September 14, 2021
Issue PDF
41
9
Click the title above for a link to open the Pharmaceutical Executive September 2021 issue in an interactive PDF format.
September 14, 2021
Back Page
41
9
Scientific advances are benefiting cancer patients, but it will take a pandemic-like response to ensure patients everywhere have access.
September 14, 2021
Features
41
9
Though M&A activity and equity market outputs have been mixed, and pandemic challenges linger on, the outlooks for pharma and biotech remain stable—driven by R&D gains, record IPO levels.
September 14, 2021
Features
41
9
Commercializing an orphan drug can be challenging, however, using a framework and a checklist that incorporates the right elements can prove beneficial.
September 14, 2021
Features
41
9
Challenge assumptions and reset expectations when it comes to pre-launch SG&A investment to increase the odds of commercial success.
September 14, 2021
Features
41
9
New drug aims to turn obesity into treatable chronic condition.
September 14, 2021
Features
41
9
Peanut allergies raise fears among parents, teachers, but treatment is now available.
September 14, 2021
Features
41
9
Hopeful new standard of care for advanced prostate cancer capitalizing on momentum.
September 14, 2021
Features
41
9
The aggressive strategy behind a small company’s quick ascent in migraine market.
September 14, 2021
Features
41
9
Latest disease-modifying market entrant for SMA addresses administration, access gaps.
September 14, 2021
Executive Profile
41
9
Teva CEO Kåre Schultz talks about his long industry experience tackling major strategic and operational challenges, and how he is progressing on his current mission to turn around Teva’s fortunes.
September 14, 2021
Finance
41
9
When was the last time a big pharma’s shares massively outperformed a biotech index YTD? Hint: You likely weren’t around.
September 14, 2021
Marketing
41
9
Vaccines spotlight recent resurgence of useful messaging tool.
September 14, 2021
Technology
41
9
Digital transformation in medical affairs made a sluggish start, but there is plenty to be optimistic about.
September 14, 2021
Leadership
41
9
If not addressed, effects could impact innovation, diversity.
September 14, 2021
Global Report
41
9
Treatment availability for rare disease patients under fire in Europe.
September 14, 2021
Washington Report
41
9
But accelerated approval program faces scrutiny.
September 14, 2021
From the Editor
41
9
Pharm Exec profiles five recent drug launches and announces winners of first annual APEX Awards.
August 11, 2021
Features
41
9
With opportunity and risk lurking in equal measure, today’s key considerations for biopharma startups when building their leadership teams and product go-to-market strategies are outlined.